Skip to main content
Modalis Therapeutics Corporation logo

Modalis Therapeutics Corporation — Investor Relations & Filings

Ticker · 4883 ISIN · JP3922600006 T Manufacturing
Open in API
Filings indexed 57 across all filing types
Latest filing 2022-05-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4883

About Modalis Therapeutics Corporation

https://modalistx.com/en/

Modalis Therapeutics Corporation is a biotechnology company developing precision genetic medicines for serious disorders. The company's core technology is CRISPR-GNDM®, a proprietary epigenome editing platform. This technology regulates the expression of specific genes—selectively activating or suppressing them—without altering the underlying DNA sequence or causing double-strand breaks. CRISPR-GNDM® utilizes a compact epigenome editor designed for efficient delivery to target cells using adeno-associated virus (AAV) vectors. The company advances its programs through a hybrid model of in-house development and collaborative partnerships, with a pipeline focused on therapeutic areas such as muscular disorders, cardiomyopathy, and central nervous system (CNS) disorders.

Recent filings

Filing Released Lang Actions
四半期報告書－第7期第1四半期(令和4年1月1日－令和4年3月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet, for the first quarter of the fiscal year 2022 (January 1, 2022, to March 31, 2022). It includes management analysis, stock information, and audit review information. This fits the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-13 Japanese
内部統制報告書－第6期(令和3年1月1日－令和3年12月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the framework, scope, and results of the company's internal controls over financial reporting. Since this is a standalone regulatory report regarding internal control systems and audit-related compliance rather than a full annual report or a simple announcement, it falls under the 'Audit Report / Information' category.
2022-03-29 Japanese
有価証券報告書－第6期(令和3年1月1日－令和3年12月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains detailed financial statements, management indicators, and audit information for the fiscal year ending December 31, 2021, for Modalis Therapeutics Corporation. It is a comprehensive annual filing, not an announcement or a summary. FY 2021
2022-03-29 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act of Japan. It serves as a formal certification by the CEO and CFO regarding the accuracy of the company's Annual Securities Report (Yuuka Shouken Houkokusho). Since it is a regulatory filing required by law to accompany the annual report but is not the annual report itself, and does not fit into other specific categories like M&A or dividends, it is classified as a Regulatory Filing (RNS). FY 2021
2022-03-29 Japanese
四半期報告書－第6期第3四半期(令和3年7月1日－令和3年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a Japanese 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet, income statement, and comprehensive income statement for the third quarter of the fiscal year 2021. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Japanese
四半期報告書－第6期第2四半期(令和3年4月1日－令和3年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by Modalis Therapeutics Corporation in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet, income statement, and cash flow analysis for the second quarter of the fiscal year 2021. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2021
2021-08-13 Japanese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.